FDAnews
www.fdanews.com/articles/126620-st-jude-benefits-from-troubles-faced-by-boston-scientific

St. Jude Benefits From Troubles Faced by Boston Scientific

April 29, 2010
Boston Scientific’s troubles with its implantable cardioverter defibrillators (ICDs) were St. Jude Medical’s financial gain in the first quarter of 2010. St. Jude gained $20 million to $25 million in U.S. revenue from what company CEO Dan Starks called the “Boston Debacle.” Total sales of St. Jude’s heart rhythm devices rose 11 percent to $752 million in the quarter, and sales of ICDs grew 15 percent to $452 million, the company said.
Devices & Diagnostics Letter